Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of URC102 (Epaminurad) in Gout Patients
NCT04804111Phase 2Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epaminurad in gout, hyperuricemia, sponsored by JW Pharmaceutical Corporation. Started Jan 2019; status: completed.
02
Drugs
epaminurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04804111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804111.